Walpole
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006
| Obs | Exp | SIR | 95% CI |
|
| Obs | Exp | SIR | 95% CI |
Bladder, Urinary |
|
| Melanoma of Skin |
|
| |||||
Male | 21 | 27.1 | 77.4 | (47.9-118.3) |
| Male | 19 | 16.9 | 112.4 | (67.6-175.5) |
Female | 12 | 9.7 | 123.1 | (63.5-215.0) |
| Female | 18 | 13.0 | 139.0 | (82.3-219.7) |
Brain and Other Nervous System |
|
| Multiple Myeloma |
|
| |||||
Male | 5 | 5.1 | 98.3 | (31.7-229.3) |
| Male | 1 | 4.2 | nc | (nc-nc) |
Female | 6 | 4.1 | 146.8 | (53.6-319.6) |
| Female | 6 | 3.1 | 194.5 | (71.0-423.3) |
Breast |
|
| Non-Hodgkin Lymphoma |
|
| |||||
Male | 0 | 0.9 | nc | (nc-nc) |
| Male | 16 | 14.5 | 110.6 | (63.2-179.6) |
Female | 96 | 94.2 | 102.0 | (82.6-124.5) |
| Female | 7 | 12.5 | 55.9 | (22.4-115.2) |
Cervix Uteri |
|
| Oral Cavity & Pharynx |
|
| |||||
|
|
|
|
|
| Male | 8 | 10.3 | 77.5 | (33.4-152.7) |
Female | 2 | 3.9 | nc | (nc-nc) |
| Female | 1 | 4.7 | nc | (nc-nc) |
Colon / Rectum |
|
| Ovary |
|
| |||||
Male | 31 | 38.1 | 81.4 | (55.3-115.5) |
|
|
|
|
|
|
Female | 35 | 35.5 | 98.6 | (68.6-137.1) |
| Female | 14 | 9.8 | 142.7 | (77.9-239.4) |
Esophagus |
|
| Pancreas |
|
| |||||
Male | 6 | 7.0 | 85.2 | (31.1-185.5) |
| Male | 8 | 8.2 | 97.6 | (42.0-192.3) |
Female | 0 | 1.9 | nc | (nc-nc) |
| Female | 2 | 8.4 | nc | (nc-nc) |
Hodgkin Lymphoma |
|
| Prostate |
|
| |||||
Male | 3 | 2.2 | nc | (nc-nc) |
| Male | 97 | 100.6 | 96.4 | (78.2-117.6) |
Female | 0 | 1.5 | nc | (nc-nc) |
|
|
|
|
|
|
Kidney & Renal Pelvis |
|
| Stomach |
|
| |||||
Male | 25 | 12.8 | 194.8 | (126.1-287.6) |
| Male | 9 | 6.3 | 143.4 | (65.4-272.2) |
Female | 6 | 7.6 | 78.6 | (28.7-171.1) |
| Female | 3 | 3.9 | nc | (nc-nc) |
Larynx |
|
| Testis |
|
| |||||
Male | 4 | 4.3 | nc | (nc-nc) |
| Male | 3 | 3.7 | nc | (nc-nc) |
Female | 0 | 1.1 | nc | (nc-nc) |
|
|
|
|
|
|
Leukemia |
|
| Thyroid |
|
| |||||
Male | 4 | 8.9 | nc | (nc-nc) |
| Male | 5 | 4.3 | 116.6 | (37.6-272.0) |
Female | 6 | 6.8 | 88.0 | (32.2-191.6) |
| Female | 13 | 12.3 | 105.8 | (56.3-180.9) |
Liver and Intrahepatic Bile Ducts |
|
| Uteri Corpus and Uterus, NOS |
|
| |||||
Male | 3 | 6.2 | nc | (nc-nc) |
|
|
|
|
|
|
Female | 2 | 2.1 | nc | (nc-nc) |
| Female | 20 | 21.0 | 95.3 | (58.2-147.2) |
Lung and Bronchus |
|
| All Sites / Types |
|
| |||||
Male | 46 | 50.2 | 91.7 | (67.1-122.3) |
| Male | 333 | 358.9 | 92.8 | (83.1-103.3) |
Female | 55 | 46.5 | 118.2 | (89.0-153.8) |
| Female | 325 | 330.1 | 98.4 | (88.0-109.8) |
• Obs = observed case count; Exp = expected case count;
• SIR = standardized incidence ratio ( (Obs / Exp) X 100);
• 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
• Shading indicates the statistical significance of the SIR at 95% level of probability;
• nc = The SIR and 95% CI were not calculated when Obs < 5;
316
Waltham
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006
| Obs | Exp | SIR | 95% CI |
|
| Obs | Exp | SIR | 95% CI |
Bladder, Urinary |
|
| Melanoma of Skin |
|
| |||||
Male | 43 | 60.0 | 71.6 | (51.8-96.5) |
| Male | 26 | 38.1 | 68.3 | (44.6-100.1) |
Female | 22 | 23.4 | 94.2 | (59.0-142.7) |
| Female | 27 | 32.4 | 83.3 | (54.9-121.1) |
Brain and Other Nervous System |
|
| Multiple Myeloma |
|
| |||||
Male | 8 | 11.5 | 69.4 | (29.9-136.8) |
| Male | 8 | 9.4 | 85.5 | (36.8-168.5) |
Female | 9 | 9.9 | 91.0 | (41.5-172.8) |
| Female | 7 | 7.4 | 94.9 | (38.0-195.5) |
Breast |
|
| Non-Hodgkin Lymphoma |
|
| |||||
Male | 2 | 1.9 | nc | (nc-nc) |
| Male | 33 | 32.5 | 101.4 | (69.8-142.4) |
Female | 229 | 219.9 | 104.1 | (91.1-118.5) |
| Female | 34 | 30.3 | 112.4 | (77.8-157.0) |
Cervix Uteri |
|
| Oral Cavity & Pharynx |
|
| |||||
|
|
|
|
|
| Male | 29 | 22.6 | 128.3 | (85.9-184.2) |
Female | 8 | 9.8 | 81.6 | (35.1-160.8) |
| Female | 12 | 11.3 | 106.5 | (55.0-186.1) |
Colon / Rectum |
|
| Ovary |
|
| |||||
Male | 69 | 83.9 | 82.2 | (64.0-104.1) |
|
|
|
|
|
|
Female | 104 | 84.6 | 123.0 | (100.5-149.0) |
| Female | 26 | 23.4 | 111.3 | (72.7-163.1) |
Esophagus |
|
| Pancreas |
|
| |||||
Male | 11 | 15.5 | 71.1 | (35.4-127.2) |
| Male | 23 | 18.0 | 127.5 | (80.8-191.3) |
Female | 8 | 4.5 | 176.9 | (76.2-348.6) |
| Female | 18 | 20.1 | 89.6 | (53.1-141.6) |
Hodgkin Lymphoma |
|
| Prostate |
|
| |||||
Male | 6 | 6.1 | 98.0 | (35.8-213.3) |
| Male | 213 | 221.6 | 96.1 | (83.6-109.9) |
Female | 4 | 4.8 | nc | (nc-nc) |
|
|
|
|
|
|
Kidney & Renal Pelvis |
|
| Stomach |
|
| |||||
Male | 20 | 28.1 | 71.1 | (43.4-109.9) |
| Male | 12 | 13.8 | 86.7 | (44.8-151.5) |
Female | 14 | 18.2 | 76.9 | (42.0-129.1) |
| Female | 13 | 9.3 | 140.2 | (74.6-239.8) |
Larynx |
|
| Testis |
|
| |||||
Male | 9 | 9.6 | 94.1 | (43.0-178.7) |
| Male | 9 | 11.2 | 80.4 | (36.7-152.7) |
Female | 3 | 2.7 | nc | (nc-nc) |
|
|
|
|
|
|
Leukemia |
|
| Thyroid |
|
| |||||
Male | 10 | 20.1 | 49.7 | (23.8-91.4) |
| Male | 8 | 10.1 | 78.9 | (34.0-155.5) |
Female | 19 | 16.3 | 116.7 | (70.2-182.3) |
| Female | 29 | 31.5 | 92.0 | (61.6-132.2) |
Liver and Intrahepatic Bile Ducts |
|
| Uteri Corpus and Uterus, NOS |
|
| |||||
Male | 12 | 13.7 | 87.8 | (45.3-153.4) |
|
|
|
|
|
|
Female | 8 | 5.0 | 160.5 | (69.1-316.2) |
| Female | 41 | 49.3 | 83.2 | (59.7-112.9) |
Lung and Bronchus |
|
| All Sites / Types |
|
| |||||
Male | 102 | 110.8 | 92.0 | (75.0-111.7) |
| Male | 707 | 799.1 | 88.5 | (82.1-95.2) |
Female | 88 | 111.7 | 78.8 | (63.2-97.0) |
| Female | 787 | 788.7 | 99.8 | (92.9-107.0) |
• Obs = observed case count; Exp = expected case count;
• SIR = standardized incidence ratio ( (Obs / Exp) X 100);
• 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
• Shading indicates the statistical significance of the SIR at 95% level of probability;
• nc = The SIR and 95% CI were not calculated when Obs < 5;
317
Ware
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006
| Obs | Exp | SIR | 95% CI |
|
| Obs | Exp | SIR | 95% CI |
Bladder, Urinary |
|
| Melanoma of Skin |
|
| |||||
Male | 6 | 11.7 | 51.4 | (18.8-111.8) |
| Male | 6 | 7.1 | 84.5 | (30.8-183.9) |
Female | 5 | 4.6 | 108.4 | (34.9-252.9) |
| Female | 5 | 5.9 | 85.3 | (27.5-199.2) |
Brain and Other Nervous System |
|
| Multiple Myeloma |
|
| |||||
Male | 1 | 2.1 | nc | (nc-nc) |
| Male | 1 | 1.8 | nc | (nc-nc) |
Female | 2 | 1.8 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |
Breast |
|
| Non-Hodgkin Lymphoma |
|
| |||||
Male | 0 | 0.4 | nc | (nc-nc) |
| Male | 2 | 6.1 | nc | (nc-nc) |
Female | 31 | 41.7 | 74.4 | (50.5-105.6) |
| Female | 4 | 5.9 | nc | (nc-nc) |
Cervix Uteri |
|
| Oral Cavity & Pharynx |
|
| |||||
|
|
|
|
|
| Male | 5 | 4.4 | 114.5 | (36.9-267.1) |
Female | 3 | 1.7 | nc | (nc-nc) |
| Female | 1 | 2.1 | nc | (nc-nc) |
Colon / Rectum |
|
| Ovary |
|
| |||||
Male | 20 | 16.3 | 122.6 | (74.9-189.4) |
|
|
|
|
|
|
Female | 10 | 17.0 | 58.7 | (28.1-107.9) |
| Female | 7 | 4.4 | 157.4 | (63.1-324.3) |
Esophagus |
|
| Pancreas |
|
| |||||
Male | 1 | 3.0 | nc | (nc-nc) |
| Male | 1 | 3.5 | nc | (nc-nc) |
Female | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 4.0 | nc | (nc-nc) |
Hodgkin Lymphoma |
|
| Prostate |
|
| |||||
Male | 1 | 0.9 | nc | (nc-nc) |
| Male | 34 | 43.3 | 78.6 | (54.4-109.9) |
Female | 1 | 0.8 | nc | (nc-nc) |
|
|
|
|
|
|
Kidney & Renal Pelvis |
|
| Stomach |
|
| |||||
Male | 3 | 5.4 | nc | (nc-nc) |
| Male | 1 | 2.7 | nc | (nc-nc) |
Female | 2 | 3.5 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |
Larynx |
|
| Testis |
|
| |||||
Male | 2 | 1.9 | nc | (nc-nc) |
| Male | 3 | 1.5 | nc | (nc-nc) |
Female | 0 | 0.5 | nc | (nc-nc) |
|
|
|
|
|
|
Leukemia |
|
| Thyroid |
|
| |||||
Male | 2 | 3.8 | nc | (nc-nc) |
| Male | 1 | 1.8 | nc | (nc-nc) |
Female | 1 | 3.2 | nc | (nc-nc) |
| Female | 4 | 5.3 | nc | (nc-nc) |
Liver and Intrahepatic Bile Ducts |
|
| Uteri Corpus and Uterus, NOS |
|
| |||||
Male | 3 | 2.7 | nc | (nc-nc) |
|
|
|
|
|
|
Female | 2 | 1.0 | nc | (nc-nc) |
| Female | 9 | 9.3 | 96.9 | (44.2-183.9) |
Lung and Bronchus |
|
| All Sites / Types |
|
| |||||
Male | 21 | 21.5 | 97.6 | (60.4-149.3) |
| Male | 126 | 153.3 | 82.2 | (68.5-97.8) |
Female | 18 | 21.7 | 83.1 | (49.2-131.4) |
| Female | 120 | 151.2 | 79.4 | (65.8-94.9) |
• Obs = observed case count; Exp = expected case count;
• SIR = standardized incidence ratio ( (Obs / Exp) X 100);
• 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
• Shading indicates the statistical significance of the SIR at 95% level of probability;
• nc = The SIR and 95% CI were not calculated when Obs < 5;
318
Wareham
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006
| Obs | Exp | SIR | 95% CI |
|
| Obs | Exp | SIR | 95% CI |
Bladder, Urinary |
|
| Melanoma of Skin |
|
| |||||
Male | 24 | 27.3 | 88.0 | (56.4-131.0) |
| Male | 15 | 16.2 | 92.5 | (51.8-152.6) |
Female | 13 | 10.0 | 130.6 | (69.5-223.4) |
| Female | 5 | 12.9 | 38.7 | (12.5-90.2) |
Brain and Other Nervous System |
|
| Multiple Myeloma |
|
| |||||
Male | 6 | 4.7 | 126.4 | (46.2-275.2) |
| Male | 4 | 4.2 | nc | (nc-nc) |
Female | 3 | 4.0 | nc | (nc-nc) |
| Female | 2 | 3.1 | nc | (nc-nc) |
Breast |
|
| Non-Hodgkin Lymphoma |
|
| |||||
Male | 1 | 0.9 | nc | (nc-nc) |
| Male | 9 | 13.9 | 64.7 | (29.5-122.8) |
Female | 91 | 94.4 | 96.4 | (77.6-118.3) |
| Female | 14 | 12.7 | 110.3 | (60.3-185.1) |
Cervix Uteri |
|
| Oral Cavity & Pharynx |
|
| |||||
|
|
|
|
|
| Male | 12 | 10.0 | 119.8 | (61.8-209.3) |
Female | 5 | 3.8 | 130.0 | (41.9-303.4) |
| Female | 5 | 4.8 | 104.8 | (33.8-244.6) |
Colon / Rectum |
|
| Ovary |
|
| |||||
Male | 54 | 37.7 | 143.2 | (107.6-186.8) |
|
|
|
|
|
|
Female | 41 | 35.4 | 115.9 | (83.1-157.2) |
| Female | 8 | 9.9 | 81.0 | (34.9-159.7) |
Esophagus |
|
| Pancreas |
|
| |||||
Male | 10 | 7.1 | 141.8 | (67.9-260.7) |
| Male | 11 | 8.2 | 133.8 | (66.7-239.4) |
Female | 1 | 1.9 | nc | (nc-nc) |
| Female | 11 | 8.5 | 129.2 | (64.4-231.2) |
Hodgkin Lymphoma |
|
| Prostate |
|
| |||||
Male | 2 | 1.9 | nc | (nc-nc) |
| Male | 99 | 104.3 | 94.9 | (77.1-115.5) |
Female | 3 | 1.6 | nc | (nc-nc) |
|
|
|
|
|
|
Kidney & Renal Pelvis |
|
| Stomach |
|
| |||||
Male | 22 | 12.5 | 175.7 | (110.1-266.0) |
| Male | 5 | 6.2 | 80.9 | (26.1-188.7) |
Female | 9 | 7.8 | 115.1 | (52.5-218.6) |
| Female | 4 | 3.8 | nc | (nc-nc) |
Larynx |
|
| Testis |
|
| |||||
Male | 7 | 4.4 | 158.8 | (63.6-327.2) |
| Male | 3 | 3.0 | nc | (nc-nc) |
Female | 3 | 1.2 | nc | (nc-nc) |
|
|
|
|
|
|
Leukemia |
|
| Thyroid |
|
| |||||
Male | 10 | 8.6 | 116.3 | (55.7-214.0) |
| Male | 3 | 3.9 | nc | (nc-nc) |
Female | 3 | 6.7 | nc | (nc-nc) |
| Female | 9 | 12.1 | 74.5 | (34.0-141.4) |
Liver and Intrahepatic Bile Ducts |
|
| Uteri Corpus and Uterus, NOS |
|
| |||||
Male | 10 | 6.1 | 163.5 | (78.3-300.7) |
|
|
|
|
|
|
Female | 3 | 2.1 | nc | (nc-nc) |
| Female | 22 | 21.6 | 102.0 | (63.9-154.4) |
Lung and Bronchus |
|
| All Sites / Types |
|
| |||||
Male | 64 | 51.0 | 125.5 | (96.7-160.3) |
| Male | 401 | 358.4 | 111.9 | (101.2-123.4) |
Female | 55 | 48.6 | 113.1 | (85.2-147.2) |
| Female | 337 | 333.1 | 101.2 | (90.6-112.6) |
• Obs = observed case count; Exp = expected case count;
• SIR = standardized incidence ratio ( (Obs / Exp) X 100);
• 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
• Shading indicates the statistical significance of the SIR at 95% level of probability;
• nc = The SIR and 95% CI were not calculated when Obs < 5;
319
Warren
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006
| Obs | Exp | SIR | 95% CI |
|
| Obs | Exp | SIR | 95% CI |
Bladder, Urinary |
|
| Melanoma of Skin |
|
| |||||
Male | 5 | 5.5 | 90.7 | (29.2-211.6) |
| Male | 1 | 3.5 | nc | (nc-nc) |
Female | 0 | 1.8 | nc | (nc-nc) |
| Female | 6 | 2.6 | 228.0 | (83.3-496.3) |
Brain and Other Nervous System |
|
| Multiple Myeloma |
|
| |||||
Male | 2 | 1.0 | nc | (nc-nc) |
| Male | 0 | 0.9 | nc | (nc-nc) |
Female | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |
Breast |
|
| Non-Hodgkin Lymphoma |
|
| |||||
Male | 0 | 0.2 | nc | (nc-nc) |
| Male | 1 | 2.9 | nc | (nc-nc) |
Female | 19 | 18.5 | 102.8 | (61.8-160.5) |
| Female | 4 | 2.4 | nc | (nc-nc) |
Cervix Uteri |
|
| Oral Cavity & Pharynx |
|
| |||||
|
|
|
|
|
| Male | 0 | 2.1 | nc | (nc-nc) |
Female | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |
Colon / Rectum |
|
| Ovary |
|
| |||||
Male | 7 | 7.8 | 90.1 | (36.1-185.6) |
|
|
|
|
|
|
Female | 7 | 6.6 | 106.5 | (42.6-219.4) |
| Female | 1 | 1.9 | nc | (nc-nc) |
Esophagus |
|
| Pancreas |
|
| |||||
Male | 1 | 1.5 | nc | (nc-nc) |
| Male | 2 | 1.7 | nc | (nc-nc) |
Female | 2 | 0.4 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |
Hodgkin Lymphoma |
|
| Prostate |
|
| |||||
Male | 0 | 0.5 | nc | (nc-nc) |
| Male | 13 | 21.5 | 60.5 | (32.2-103.5) |
Female | 2 | 0.4 | nc | (nc-nc) |
|
|
|
|
|
|
Kidney & Renal Pelvis |
|
| Stomach |
|
| |||||
Male | 1 | 2.6 | nc | (nc-nc) |
| Male | 2 | 1.3 | nc | (nc-nc) |
Female | 4 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |
Larynx |
|
| Testis |
|
| |||||
Male | 0 | 0.9 | nc | (nc-nc) |
| Male | 0 | 0.8 | nc | (nc-nc) |
Female | 0 | 0.2 | nc | (nc-nc) |
|
|
|
|
|
|
Leukemia |
|
| Thyroid |
|
| |||||
Male | 1 | 1.8 | nc | (nc-nc) |
| Male | 1 | 0.9 | nc | (nc-nc) |
Female | 2 | 1.3 | nc | (nc-nc) |
| Female | 3 | 2.6 | nc | (nc-nc) |
Liver and Intrahepatic Bile Ducts |
|
| Uteri Corpus and Uterus, NOS |
|
| |||||
Male | 0 | 1.3 | nc | (nc-nc) |
|
|
|
|
|
|
Female | 0 | 0.4 | nc | (nc-nc) |
| Female | 4 | 4.2 | nc | (nc-nc) |
Lung and Bronchus |
|
| All Sites / Types |
|
| |||||
Male | 5 | 10.3 | 48.3 | (15.6-112.8) |
| Male | 47 | 74.4 | 63.2 | (46.4-84.0) |
Female | 14 | 8.9 | 156.6 | (85.5-262.8) |
| Female | 74 | 64.1 | 115.4 | (90.6-144.9) |
• Obs = observed case count; Exp = expected case count;
• SIR = standardized incidence ratio ( (Obs / Exp) X 100);
• 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
• Shading indicates the statistical significance of the SIR at 95% level of probability;
• nc = The SIR and 95% CI were not calculated when Obs < 5;
320
Warwick
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006
| Obs | Exp | SIR | 95% CI |
|
| Obs | Exp | SIR | 95% CI |
Bladder, Urinary |
|
| Melanoma of Skin |
|
| |||||
Male | 0 | 0.8 | nc | (nc-nc) |
| Male | 0 | 0.5 | nc | (nc-nc) |
Female | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |
Brain and Other Nervous System |
|
| Multiple Myeloma |
|
| |||||
Male | 0 | 0.2 | nc | (nc-nc) |
| Male | 2 | 0.1 | nc | (nc-nc) |
Female | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |
Breast |
|
| Non-Hodgkin Lymphoma |
|
| |||||
Male | 0 | 0.0 | nc | (nc-nc) |
| Male | 0 | 0.5 | nc | (nc-nc) |
Female | 1 | 3.0 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |
Cervix Uteri |
|
| Oral Cavity & Pharynx |
|
| |||||
|
|
|
|
|
| Male | 0 | 0.4 | nc | (nc-nc) |
Female | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |
Colon / Rectum |
|
| Ovary |
|
| |||||
Male | 1 | 1.2 | nc | (nc-nc) |
|
|
|
|
|
|
Female | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |
Esophagus |
|
| Pancreas |
|
| |||||
Male | 1 | 0.2 | nc | (nc-nc) |
| Male | 1 | 0.3 | nc | (nc-nc) |
Female | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |
Hodgkin Lymphoma |
|
| Prostate |
|
| |||||
Male | 0 | 0.1 | nc | (nc-nc) |
| Male | 2 | 3.3 | nc | (nc-nc) |
Female | 0 | 0.1 | nc | (nc-nc) |
|
|
|
|
|
|
Kidney & Renal Pelvis |
|
| Stomach |
|
| |||||
Male | 0 | 0.4 | nc | (nc-nc) |
| Male | 0 | 0.2 | nc | (nc-nc) |
Female | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |
Larynx |
|
| Testis |
|
| |||||
Male | 0 | 0.1 | nc | (nc-nc) |
| Male | 0 | 0.1 | nc | (nc-nc) |
Female | 0 | 0.0 | nc | (nc-nc) |
|
|
|
|
|
|
Leukemia |
|
| Thyroid |
|
| |||||
Male | 0 | 0.3 | nc | (nc-nc) |
| Male | 0 | 0.1 | nc | (nc-nc) |
Female | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |
Liver and Intrahepatic Bile Ducts |
|
| Uteri Corpus and Uterus, NOS |
|
| |||||
Male | 1 | 0.2 | nc | (nc-nc) |
|
|
|
|
|
|
Female | 0 | 0.1 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) |
Lung and Bronchus |
|
| All Sites / Types |
|
| |||||
Male | 1 | 1.6 | nc | (nc-nc) |
| Male | 9 | 11.5 | 78.2 | (35.7-148.5) |
Female | 0 | 1.3 | nc | (nc-nc) |
| Female | 4 | 9.7 | nc | (nc-nc) |
• Obs = observed case count; Exp = expected case count;
• SIR = standardized incidence ratio ( (Obs / Exp) X 100);
• 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
• Shading indicates the statistical significance of the SIR at 95% level of probability;
• nc = The SIR and 95% CI were not calculated when Obs < 5;
321
| Female | 0 | 0.1 | nc | (nc-nc) | |||||
Breast |
|
| Non-Hodgkin Lymphoma |
|
| |||||
Male | 0 | 0.0 | nc | (nc-nc) |
| Male | 0 | 0.3 | nc | (nc-nc) |
Female | 0 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |
Cervix Uteri |
|
| Oral Cavity & Pharynx |
|
| |||||
|
|
|
|
|
| Male | 0 | 0.3 | nc | (nc-nc) |
Female | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |
Colon / Rectum |
|
| Ovary |
|
| |||||
Male | 2 | 0.9 | nc | (nc-nc) |
|
|
|
|
|
|
Female | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |
Esophagus |
|
| Pancreas |
|
| |||||
Male | 0 | 0.2 | nc | (nc-nc) |
| Male | 0 | 0.2 | nc | (nc-nc) |
Female | 0 | 0.0 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) |
Hodgkin Lymphoma |
|
| Prostate |
|
| |||||
Male | 0 | 0.1 | nc | (nc-nc) |
| Male | 3 | 2.5 | nc | (nc-nc) |
Female | 0 | 0.0 | nc | (nc-nc) |
|
|
|
|
|
|
Kidney & Renal Pelvis |
|
| Stomach |
|
| |||||
Male | 0 | 0.3 | nc | (nc-nc) |
| Male | 0 | 0.1 | nc | (nc-nc) |
Female | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |
Larynx |
|
| Testis |
|
| |||||
Male | 0 | 0.1 | nc | (nc-nc) |
| Male | 0 | 0.1 | nc | (nc-nc) |
Female | 0 | 0.0 | nc | (nc-nc) |
|
|
|
|
|
|
Leukemia |
|
| Thyroid |
|
| |||||
Male | 0 | 0.2 | nc | (nc-nc) |
| Male | 0 | 0.1 | nc | (nc-nc) |
Female | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |
Liver and Intrahepatic Bile Ducts |
|
| Uteri Corpus and Uterus, NOS |
|
| |||||
Male | 0 | 0.2 | nc | (nc-nc) |
|
|
|
|
|
|
Female | 0 | 0.0 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |
Lung and Bronchus |
|
| All Sites / Types |
|
| |||||
Male | 1 | 1.1 | nc | (nc-nc) |
| Male | 7 | 8.4 | 83.0 | (33.2-171.0) |
Female | 0 | 0.9 | nc | (nc-nc) |
| Female | 5 | 6.6 | 75.3 | (24.3-175.7) |
• Obs = observed case count; Exp = expected case count;
• SIR = standardized incidence ratio ( (Obs / Exp) X 100);
• 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
• Shading indicates the statistical significance of the SIR at 95% level of probability;
• nc = The SIR and 95% CI were not calculated when Obs < 5;
322
Washington | Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006 |
| Obs | Exp | SIR | |||||
|
| Obs | Exp | SIR | 95% CI | |||||
Bladder, Urinary |
|
| Melanoma of Skin |
|
| Male | 0 | 0.6 | nc | |
| Male | 1 | 0.4 | nc | (nc-nc) | Female | 0 | 0.2 | nc | |
| Female | 1 | 0.3 | nc | (nc-nc) | |||||
Brain and Other Nervous System |
|
| Multiple Myeloma |
|
| Male | 0 | 0.1 | nc | |
| Male | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.1 | nc | |
Esophagus |
|
| Pancreas |
|
| |||||
Male | 0 | 0.3 | nc | (nc-nc) |
| Male | 1 | 0.3 | nc | (nc-nc) |
Female | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |
Hodgkin Lymphoma |
|
| Prostate |
|
| |||||
Male | 0 | 0.1 | nc | (nc-nc) |
| Male | 2 | 3.7 | nc | (nc-nc) |
Female | 0 | 0.1 | nc | (nc-nc) |
|
|
|
|
|
|
Kidney & Renal Pelvis |
|
| Stomach |
|
| |||||
Male | 0 | 0.5 | nc | (nc-nc) |
| Male | 1 | 0.2 | nc | (nc-nc) |
Female | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |
Larynx |
|
| Testis |
|
| |||||
Male | 0 | 0.2 | nc | (nc-nc) |
| Male | 0 | 0.2 | nc | (nc-nc) |
Female | 0 | 0.0 | nc | (nc-nc) |
|
|
|
|
|
|
Leukemia |
|
| Thyroid |
|
| |||||
Male | 0 | 0.3 | nc | (nc-nc) |
| Male | 0 | 0.2 | nc | (nc-nc) |
Female | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |
Liver and Intrahepatic Bile Ducts |
|
| Uteri Corpus and Uterus, NOS |
|
| |||||
Male | 0 | 0.3 | nc | (nc-nc) |
|
|
|
|
|
|
Female | 0 | 0.1 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |
Lung and Bronchus |
|
| All Sites / Types |
|
| |||||
Male | 0 | 1.5 | nc | (nc-nc) |
| Male | 9 | 12.6 | 71.5 | (32.6-135.7) |
Female | 1 | 1.1 | nc | (nc-nc) |
| Female | 11 | 10.1 | 109.1 | (54.4-195.2) |
95% CI
(nc-nc)
(nc-nc)
(nc-nc)
(nc-nc)
Watertown
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006
| Obs | Exp | SIR | 95% CI |
|
| Obs | Exp | SIR | 95% CI |
Bladder, Urinary |
|
| Melanoma of Skin |
|
| |||||
Male | 50 | 38.1 | 131.4 | (97.5-173.2) |
| Male | 9 | 22.7 | 39.6 | (18.1-75.1) |
Female | 15 | 16.5 | 90.9 | (50.9-150.0) |
| Female | 19 | 21.2 | 89.8 | (54.0-140.3) |
Brain and Other Nervous System |
|
| Multiple Myeloma |
|
| |||||
Male | 4 | 6.6 | nc | (nc-nc) |
| Male | 2 | 5.8 | nc | (nc-nc) |
Female | 4 | 6.3 | nc | (nc-nc) |
| Female | 2 | 5.2 | nc | (nc-nc) |
Breast |
|
| Non-Hodgkin Lymphoma |
|
| |||||
Male | 1 | 1.2 | nc | (nc-nc) |
| Male | 15 | 19.5 | 76.8 | (42.9-126.6) |
Female | 134 | 144.6 | 92.7 | (77.7-109.8) |
| Female | 21 | 20.8 | 100.7 | (62.3-154.0) |
Cervix Uteri |
|
| Oral Cavity & Pharynx |
|
| |||||
|
|
|
|
|
| Male | 9 | 13.0 | 69.1 | (31.5-131.1) |
Female | 5 | 6.3 | 79.7 | (25.7-185.9) |
| Female | 10 | 7.5 | 132.6 | (63.5-243.8) |
Colon / Rectum |
|
| Ovary |
|
| |||||
Male | 43 | 52.0 | 82.7 | (59.9-111.5) |
|
|
|
|
|
|
Female | 48 | 60.4 | 79.5 | (58.6-105.4) |
| Female | 20 | 15.5 | 129.3 | (78.9-199.6) |
Esophagus |
|
| Pancreas |
|
| |||||
Male | 7 | 9.4 | 74.6 | (29.9-153.8) |
| Male | 14 | 11.2 | 125.2 | (68.4-210.0) |
Female | 5 | 3.2 | 155.5 | (50.1-362.9) |
| Female | 14 | 14.3 | 97.7 | (53.4-164.0) |
Hodgkin Lymphoma |
|
| Prostate |
|
| |||||
Male | 5 | 3.2 | 156.7 | (50.5-365.7) |
| Male | 118 | 133.2 | 88.6 | (73.3-106.1) |
Female | 4 | 2.8 | nc | (nc-nc) |
|
|
|
|
|
|
Kidney & Renal Pelvis |
|
| Stomach |
|
| |||||
Male | 16 | 16.8 | 95.1 | (54.3-154.4) |
| Male | 7 | 8.7 | 80.1 | (32.1-165.1) |
Female | 14 | 12.3 | 113.6 | (62.1-190.7) |
| Female | 5 | 6.7 | 74.3 | (24.0-173.5) |
Larynx |
|
| Testis |
|
| |||||
Male | 6 | 5.8 | 104.3 | (38.1-227.0) |
| Male | 6 | 5.9 | 102.2 | (37.3-222.4) |
Female | 2 | 1.8 | nc | (nc-nc) |
|
|
|
|
|
|
Leukemia |
|
| Thyroid |
|
| |||||
Male | 8 | 12.1 | 66.1 | (28.5-130.3) |
| Male | 5 | 5.7 | 88.4 | (28.5-206.2) |
Female | 10 | 11.2 | 89.5 | (42.9-164.6) |
| Female | 20 | 19.5 | 102.4 | (62.5-158.1) |
Liver and Intrahepatic Bile Ducts |
|
| Uteri Corpus and Uterus, NOS |
|
| |||||
Male | 6 | 8.1 | 74.3 | (27.1-161.8) |
|
|
|
|
|
|
Female | 1 | 3.5 | nc | (nc-nc) |
| Female | 29 | 31.8 | 91.1 | (61.0-130.8) |
Lung and Bronchus |
|
| All Sites / Types |
|
| |||||
Male | 65 | 69.3 | 93.9 | (72.4-119.6) |
| Male | 436 | 485.6 | 89.8 | (81.5-98.6) |
Female | 72 | 77.2 | 93.2 | (72.9-117.4) |
| Female | 490 | 532.8 | 92.0 | (84.0-100.5) |
• Obs = observed case count; Exp = expected case count;
• SIR = standardized incidence ratio ( (Obs / Exp) X 100);
• 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
• Shading indicates the statistical significance of the SIR at 95% level of probability;
• nc = The SIR and 95% CI were not calculated when Obs < 5;
323
Wayland
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006
| Obs | Exp | SIR | 95% CI |
|
| Obs | Exp | SIR | 95% CI | |
Bladder, Urinary |
|
| Melanoma of Skin |
|
| ||||||
Male | 21 | 16.4 | 128.0 | (79.2-195.7) |
| Male | 13 | 10.0 | 129.5 | (68.9-221.4) | |
Female | 3 | 5.5 | nc | (nc-nc) |
| Female | 13 | 7.7 | 168.1 | (89.4-287.5) | |
Brain and Other Nervous System |
|
| Multiple Myeloma |
|
| ||||||
Male | 2 | 3.0 | nc | (nc-nc) |
| Male | 4 | 2.6 | nc | (nc-nc) | |
Female | 4 | 2.4 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) | |
Breast |
|
| Non-Hodgkin Lymphoma |
|
| ||||||
Male | 1 | 0.5 | nc | (nc-nc) |
| Male | 13 | 8.6 | 151.2 | (80.4-258.6) | |
Female | 80 | 58.2 | 137.5 | (109.1-171.2) |
| Female | 7 | 7.2 | 96.9 | (38.8-199.7) | |
Cervix Uteri |
|
| Oral Cavity & Pharynx |
|
| ||||||
|
|
|
|
|
| Male | 6 | 6.4 | 93.7 | (34.2-203.9) | |
Female | 1 | 2.4 | nc | (nc-nc) |
| Female | 0 | 2.8 | nc | (nc-nc) | |
Colon / Rectum |
|
| Ovary |
|
| ||||||
Male | 22 | 23.1 | 95.4 | (59.7-144.4) |
|
|
|
|
|
| |
Female | 22 | 19.9 | 110.4 | (69.2-167.2) |
| Female | 13 | 5.9 | 218.7 | (116.4-374.1) | |
Esophagus |
|
| Pancreas |
|
| ||||||
Male | 2 | 4.4 | nc | (nc-nc) |
| Male | 4 | 5.0 | nc | (nc-nc) | |
Female | 0 | 1.1 | nc | (nc-nc) |
| Female | 2 | 4.8 | nc | (nc-nc) | |
Hodgkin Lymphoma |
|
| Prostate |
|
| ||||||
Male | 2 | 1.1 | nc | (nc-nc) |
| Male | 60 | 63.5 | 94.5 | (72.1-121.7) | |
Female | 1 | 0.8 | nc | (nc-nc) |
|
|
|
|
|
| |
Kidney & Renal Pelvis |
|
| Stomach |
|
| ||||||
Male | 3 | 7.8 | nc | (nc-nc) |
| Male | 2 | 3.7 | nc | (nc-nc) | |
Female | 3 | 4.6 | nc | (nc-nc) |
| Female | 1 | 2.1 | nc | (nc-nc) | |
Larynx |
|
| Testis |
|
| ||||||
Male | 2 | 2.7 | nc | (nc-nc) |
| Male | 2 | 1.7 | nc | (nc-nc) | |
Female | 0 | 0.7 | nc | (nc-nc) |
|
|
|
|
|
| |
Leukemia |
|
| Thyroid |
|
| ||||||
Male | 4 | 5.3 | nc | (nc-nc) |
| Male | 1 | 2.5 | nc | (nc-nc) | |
Female | 7 | 3.9 | 181.6 | (72.8-374.2) |
| Female | 15 | 7.6 | 198.6 | (111.1-327.5) | |
Liver and Intrahepatic Bile Ducts |
|
| Uteri Corpus and Uterus, NOS |
|
| ||||||
Male | 2 | 3.9 | nc | (nc-nc) |
|
|
|
|
|
| |
Female | 1 | 1.2 | nc | (nc-nc) |
| Female | 15 | 13.2 | 113.9 | (63.7-187.9) | |
Lung and Bronchus |
|
| All Sites / Types |
|
| ||||||
Male | 22 | 30.8 | 71.4 | (44.7-108.1) |
| Male | 200 | 219.0 | 91.3 | (79.1-104.9) | |
Female | 24 | 27.3 | 87.9 | (56.3-130.9) |
| Female | 225 | 196.0 | 114.8 | (100.3-130.8) | |
• Obs = observed case count; Exp = expected case count;
• SIR = standardized incidence ratio ( (Obs / Exp) X 100);
• 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
• Shading indicates the statistical significance of the SIR at 95% level of probability;
• nc = The SIR and 95% CI were not calculated when Obs < 5;
324
Webster
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006
| Obs | Exp | SIR | 95% CI |
|
| Obs | Exp | SIR | 95% CI |
Bladder, Urinary |
|
| Melanoma of Skin |
|
| |||||
Male | 21 | 20.4 | 103.0 | (63.8-157.5) |
| Male | 10 | 12.2 | 82.2 | (39.4-151.2) |
Female | 10 | 8.2 | 122.4 | (58.6-225.2) |
| Female | 2 | 10.2 | nc | (nc-nc) |
Brain and Other Nervous System |
|
| Multiple Myeloma |
|
| |||||
Male | 4 | 3.6 | nc | (nc-nc) |
| Male | 2 | 3.1 | nc | (nc-nc) |
Female | 2 | 3.2 | nc | (nc-nc) |
| Female | 3 | 2.6 | nc | (nc-nc) |
Breast |
|
| Non-Hodgkin Lymphoma |
|
| |||||
Male | 0 | 0.6 | nc | (nc-nc) |
| Male | 8 | 10.5 | 76.0 | (32.7-149.8) |
Female | 68 | 71.8 | 94.8 | (73.6-120.1) |
| Female | 13 | 10.4 | 125.4 | (66.7-214.4) |
Cervix Uteri |
|
| Oral Cavity & Pharynx |
|
| |||||
|
|
|
|
|
| Male | 6 | 7.3 | 81.9 | (29.9-178.2) |
Female | 6 | 3.0 | 203.2 | (74.2-442.4) |
| Female | 4 | 3.7 | nc | (nc-nc) |
Colon / Rectum |
|
| Ovary |
|
| |||||
Male | 30 | 28.2 | 106.4 | (71.8-151.9) |
|
|
|
|
|
|
Female | 32 | 30.4 | 105.4 | (72.1-148.8) |
| Female | 5 | 7.7 | 65.0 | (21.0-151.7) |
Esophagus |
|
| Pancreas |
|
| |||||
Male | 7 | 5.1 | 136.0 | (54.5-280.2) |
| Male | 10 | 6.1 | 164.4 | (78.7-302.4) |
Female | 3 | 1.6 | nc | (nc-nc) |
| Female | 6 | 7.2 | 83.9 | (30.6-182.6) |
Hodgkin Lymphoma |
|
| Prostate |
|
| |||||
Male | 2 | 1.6 | nc | (nc-nc) |
| Male | 64 | 72.7 | 88.0 | (67.7-112.3) |
Female | 1 | 1.3 | nc | (nc-nc) |
|
|
|
|
|
|
Kidney & Renal Pelvis |
|
| Stomach |
|
| |||||
Male | 8 | 9.2 | 86.9 | (37.4-171.2) |
| Male | 4 | 4.7 | nc | (nc-nc) |
Female | 7 | 6.1 | 115.0 | (46.1-237.1) |
| Female | 2 | 3.4 | nc | (nc-nc) |
Larynx |
|
| Testis |
|
| |||||
Male | 3 | 3.1 | nc | (nc-nc) |
| Male | 1 | 2.6 | nc | (nc-nc) |
Female | 2 | 0.9 | nc | (nc-nc) |
|
|
|
|
|
|
Leukemia |
|
| Thyroid |
|
| |||||
Male | 13 | 6.6 | 197.8 | (105.2-338.2) |
| Male | 2 | 3.0 | nc | (nc-nc) |
Female | 7 | 5.7 | 123.4 | (49.5-254.4) |
| Female | 2 | 9.1 | nc | (nc-nc) |
Liver and Intrahepatic Bile Ducts |
|
| Uteri Corpus and Uterus, NOS |
|
| |||||
Male | 1 | 4.5 | nc | (nc-nc) |
|
|
|
|
|
|
Female | 2 | 1.7 | nc | (nc-nc) |
| Female | 16 | 15.8 | 101.1 | (57.7-164.1) |
Lung and Bronchus |
|
| All Sites / Types |
|
| |||||
Male | 35 | 37.1 | 94.3 | (65.7-131.1) |
| Male | 256 | 262.4 | 97.6 | (86.0-110.3) |
Female | 34 | 37.8 | 89.9 | (62.2-125.6) |
| Female | 254 | 263.8 | 96.3 | (84.8-108.9) |
• Obs = observed case count; Exp = expected case count;
• SIR = standardized incidence ratio ( (Obs / Exp) X 100);
• 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
• Shading indicates the statistical significance of the SIR at 95% level of probability;
• nc = The SIR and 95% CI were not calculated when Obs < 5;
325
Wellesley
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006
| Obs | Exp | SIR | 95% CI |
|
| Obs | Exp | SIR | 95% CI |
Bladder, Urinary |
|
| Melanoma of Skin |
|
| |||||
Male | 19 | 29.6 | 64.3 | (38.7-100.4) |
| Male | 38 | 18.0 | 211.3 | (149.5-290.0) |
Female | 9 | 11.3 | 79.8 | (36.4-151.5) |
| Female | 17 | 15.4 | 110.6 | (64.4-177.0) |
Brain and Other Nervous System |
|
| Multiple Myeloma |
|
| |||||
Male | 3 | 5.4 | nc | (nc-nc) |
| Male | 5 | 4.6 | 107.8 | (34.7-251.5) |
Female | 1 | 5.0 | nc | (nc-nc) |
| Female | 2 | 3.6 | nc | (nc-nc) |
Breast |
|
| Non-Hodgkin Lymphoma |
|
| |||||
Male | 2 | 1.0 | nc | (nc-nc) |
| Male | 12 | 15.5 | 77.5 | (40.0-135.5) |
Female | 117 | 109.4 | 106.9 | (88.4-128.1) |
| Female | 11 | 14.7 | 74.9 | (37.4-134.1) |
Cervix Uteri |
|
| Oral Cavity & Pharynx |
|
| |||||
|
|
|
|
|
| Male | 14 | 11.3 | 123.5 | (67.4-207.1) |
Female | 1 | 4.6 | nc | (nc-nc) |
| Female | 8 | 5.5 | 144.9 | (62.4-285.6) |
Colon / Rectum |
|
| Ovary |
|
| |||||
Male | 31 | 41.6 | 74.6 | (50.7-105.9) |
|
|
|
|
|
|
Female | 38 | 41.2 | 92.1 | (65.2-126.5) |
| Female | 11 | 11.6 | 95.0 | (47.4-170.0) |
Esophagus |
|
| Pancreas |
|
| |||||
Male | 4 | 7.7 | nc | (nc-nc) |
| Male | 11 | 9.0 | 122.5 | (61.1-219.2) |
Female | 4 | 2.2 | nc | (nc-nc) |
| Female | 9 | 9.8 | 92.0 | (42.0-174.7) |
Hodgkin Lymphoma |
|
| Prostate |
|
| |||||
Male | 5 | 2.1 | 238.0 | (76.7-555.4) |
| Male | 140 | 111.8 | 125.2 | (105.4-147.8) |
Female | 1 | 2.3 | nc | (nc-nc) |
|
|
|
|
|
|
Kidney & Renal Pelvis |
|
| Stomach |
|
| |||||
Male | 16 | 13.9 | 115.1 | (65.7-186.9) |
| Male | 4 | 6.8 | nc | (nc-nc) |
Female | 6 | 8.9 | 67.5 | (24.6-146.9) |
| Female | 3 | 4.5 | nc | (nc-nc) |
Larynx |
|
| Testis |
|
| |||||
Male | 1 | 4.8 | nc | (nc-nc) |
| Male | 3 | 3.2 | nc | (nc-nc) |
Female | 1 | 1.3 | nc | (nc-nc) |
|
|
|
|
|
|
Leukemia |
|
| Thyroid |
|
| |||||
Male | 16 | 9.6 | 166.1 | (94.9-269.7) |
| Male | 5 | 4.4 | 113.8 | (36.7-265.6) |
Female | 4 | 8.1 | nc | (nc-nc) |
| Female | 17 | 14.8 | 115.2 | (67.0-184.4) |
Liver and Intrahepatic Bile Ducts |
|
| Uteri Corpus and Uterus, NOS |
|
| |||||
Male | 6 | 6.9 | 86.7 | (31.6-188.6) |
|
|
|
|
|
|
Female | 3 | 2.4 | nc | (nc-nc) |
| Female | 16 | 24.5 | 65.4 | (37.3-106.2) |
Lung and Bronchus |
|
| All Sites / Types |
|
| |||||
Male | 19 | 54.8 | 34.6 | (20.8-54.1) |
| Male | 378 | 391.1 | 96.7 | (87.2-106.9) |
Female | 23 | 53.9 | 42.7 | (27.0-64.0) |
| Female | 334 | 385.7 | 86.6 | (77.6-96.4) |
• Obs = observed case count; Exp = expected case count;
• SIR = standardized incidence ratio ( (Obs / Exp) X 100);
• 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
• Shading indicates the statistical significance of the SIR at 95% level of probability;
• nc = The SIR and 95% CI were not calculated when Obs < 5;
326
Wellfleet
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006
| Obs | Exp | SIR | 95% CI |
|
| Obs | Exp | SIR | 95% CI |
Bladder, Urinary |
|
| Melanoma of Skin |
|
| |||||
Male | 11 | 5.0 | 221.2 | (110.3-395.9) |
| Male | 1 | 2.7 | nc | (nc-nc) |
Female | 2 | 1.7 | nc | (nc-nc) |
| Female | 7 | 2.0 | 345.5 | (138.4-712.0) |
Brain and Other Nervous System |
|
| Multiple Myeloma |
|
| |||||
Male | 1 | 0.7 | nc | (nc-nc) |
| Male | 1 | 0.7 | nc | (nc-nc) |
Female | 2 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |
Breast |
|
| Non-Hodgkin Lymphoma |
|
| |||||
Male | 1 | 0.2 | nc | (nc-nc) |
| Male | 2 | 2.4 | nc | (nc-nc) |
Female | 16 | 15.3 | 104.3 | (59.6-169.4) |
| Female | 2 | 2.1 | nc | (nc-nc) |
Cervix Uteri |
|
| Oral Cavity & Pharynx |
|
| |||||
|
|
|
|
|
| Male | 0 | 1.6 | nc | (nc-nc) |
Female | 1 | 0.6 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |
Colon / Rectum |
|
| Ovary |
|
| |||||
Male | 5 | 6.7 | 74.4 | (24.0-173.5) |
|
|
|
|
|
|
Female | 3 | 5.9 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |
Esophagus |
|
| Pancreas |
|
| |||||
Male | 1 | 1.2 | nc | (nc-nc) |
| Male | 2 | 1.5 | nc | (nc-nc) |
Female | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |
Hodgkin Lymphoma |
|
| Prostate |
|
| |||||
Male | 0 | 0.3 | nc | (nc-nc) |
| Male | 33 | 17.4 | 189.2 | (130.2-265.7) |
Female | 0 | 0.2 | nc | (nc-nc) |
|
|
|
|
|
|
Kidney & Renal Pelvis |
|
| Stomach |
|
| |||||
Male | 0 | 2.1 | nc | (nc-nc) |
| Male | 3 | 1.1 | nc | (nc-nc) |
Female | 0 | 1.3 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |
Larynx |
|
| Testis |
|
| |||||
Male | 1 | 0.7 | nc | (nc-nc) |
| Male | 0 | 0.4 | nc | (nc-nc) |
Female | 0 | 0.2 | nc | (nc-nc) |
|
|
|
|
|
|
Leukemia |
|
| Thyroid |
|
| |||||
Male | 2 | 1.5 | nc | (nc-nc) |
| Male | 0 | 0.6 | nc | (nc-nc) |
Female | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |
Liver and Intrahepatic Bile Ducts |
|
| Uteri Corpus and Uterus, NOS |
|
| |||||
Male | 1 | 1.0 | nc | (nc-nc) |
|
|
|
|
|
|
Female | 2 | 0.3 | nc | (nc-nc) |
| Female | 6 | 3.5 | 171.2 | (62.5-372.6) |
Lung and Bronchus |
|
| All Sites / Types |
|
| |||||
Male | 5 | 9.0 | 55.5 | (17.9-129.6) |
| Male | 74 | 61.7 | 120.0 | (94.2-150.7) |
Female | 8 | 8.1 | 99.0 | (42.6-195.1) |
| Female | 60 | 54.2 | 110.7 | (84.5-142.5) |
• Obs = observed case count; Exp = expected case count;
• SIR = standardized incidence ratio ( (Obs / Exp) X 100);
• 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
• Shading indicates the statistical significance of the SIR at 95% level of probability;
• nc = The SIR and 95% CI were not calculated when Obs < 5;
327
• Obs = observed case count; Exp = expected case count;
• SIR = standardized incidence ratio ( (Obs / Exp) X 100);
• 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
• Shading indicates the statistical significance of the SIR at 95% level of probability;
• nc = The SIR and 95% CI were not calculated when Obs < 5;
328
Wendell | Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006 |
| Obs | Exp | SIR | |||||
|
| Obs | Exp | SIR | 95% CI | |||||
Bladder, Urinary |
|
| Melanoma of Skin |
|
| Male | 0 | 0.8 | nc | |
| Male | 2 | 0.6 | nc | (nc-nc) | Female | 0 | 0.2 | nc | |
| Female | 0 | 0.5 | nc | (nc-nc) | |||||
Brain and Other Nervous System |
|
| Multiple Myeloma |
|
| Male | 0 | 0.2 | nc | |
| Male | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.1 | nc | |
| Female | 0 | 0.1 | nc | (nc-nc) | |||||
Breast |
|
| Non-Hodgkin Lymphoma |
|
| Male | 0 | 0.0 | nc | |
| Male | 0 | 0.5 | nc | (nc-nc) | Female | 5 | 3.4 | 148.7 | |
| Female | 0 | 0.3 | nc | (nc-nc) | |||||
Cervix Uteri |
|
| Oral Cavity & Pharynx |
|
|
|
|
|
| |
| Male | 2 | 0.4 | nc | (nc-nc) | Female | 0 | 0.2 | nc | |
| Female | 0 | 0.1 | nc | (nc-nc) | |||||
Colon / Rectum |
|
| Ovary |
|
| Male | 0 | 1.3 | nc | |
|
|
|
|
|
| Female | 2 | 0.8 | nc | |
| Female | 0 | 0.3 | nc | (nc-nc) | |||||
Male | 2 | 5.4 | nc | (nc-nc) |
| Male | 4 | 4.4 | nc | (nc-nc) |
Female | 1 | 1.4 | nc | (nc-nc) |
|
|
|
|
|
|
Leukemia |
|
| Thyroid |
|
| |||||
Male | 12 | 10.9 | 109.6 | (56.6-191.5) |
| Male | 4 | 5.0 | nc | (nc-nc) |
Female | 5 | 8.7 | 57.7 | (18.6-134.7) |
| Female | 12 | 15.3 | 78.5 | (40.5-137.1) |
Liver and Intrahepatic Bile Ducts |
|
| Uteri Corpus and Uterus, NOS |
|
| |||||
Male | 2 | 7.6 | nc | (nc-nc) |
|
|
|
|
|
|
Female | 3 | 2.7 | nc | (nc-nc) |
| Female | 19 | 26.3 | 72.3 | (43.5-112.8) |
Lung and Bronchus |
|
| All Sites / Types |
|
| |||||
Male | 62 | 62.7 | 98.8 | (75.7-126.7) |
| Male | 435 | 443.7 | 98.0 | (89.0-107.7) |
Female | 53 | 60.5 | 87.6 | (65.6-114.6) |
| Female | 380 | 419.3 | 90.6 | (81.7-100.2) |
95% CI
(nc-nc)
(nc-nc)
(nc-nc)
(nc-nc)
(nc-nc)
(47.9-347.1)
(nc-nc)
(nc-nc)
(nc-nc)
Wenham
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006
| Obs | Exp | SIR | 95% CI |
|
| Obs | Exp | SIR | 95% CI |
Bladder, Urinary |
|
| Melanoma of Skin |
|
| |||||
Male | 4 | 5.1 | nc | (nc-nc) |
| Male | 5 | 3.0 | 166.9 | (53.8-389.4) |
Female | 2 | 1.8 | nc | (nc-nc) |
| Female | 9 | 2.4 | 377.3 | (172.2-716.4) |
Brain and Other Nervous System |
|
| Multiple Myeloma |
|
| |||||
Male | 4 | 0.9 | nc | (nc-nc) |
| Male | 0 | 0.8 | nc | (nc-nc) |
Female | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |
Breast |
|
| Non-Hodgkin Lymphoma |
|
| |||||
Male | 0 | 0.2 | nc | (nc-nc) |
| Male | 2 | 2.6 | nc | (nc-nc) |
Female | 15 | 16.7 | 89.6 | (50.1-147.7) |
| Female | 2 | 2.3 | nc | (nc-nc) |
Cervix Uteri |
|
| Oral Cavity & Pharynx |
|
| |||||
|
|
|
|
|
| Male | 3 | 1.8 | nc | (nc-nc) |
Female | 1 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |
Colon / Rectum |
|
| Ovary |
|
| |||||
Male | 5 | 7.0 | 71.2 | (23.0-166.2) |
|
|
|
|
|
|
Female | 14 | 6.4 | 219.6 | (120.0-368.5) |
| Female | 1 | 1.8 | nc | (nc-nc) |
Esophagus |
|
| Pancreas |
|
| |||||
Male | 1 | 1.3 | nc | (nc-nc) |
| Male | 1 | 1.5 | nc | (nc-nc) |
Female | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |
Hodgkin Lymphoma |
|
| Prostate |
|
| |||||
Male | 2 | 0.4 | nc | (nc-nc) |
| Male | 18 | 18.3 | 98.5 | (58.4-155.7) |
Female | 0 | 0.4 | nc | (nc-nc) |
|
|
|
|
|
|
Kidney & Renal Pelvis |
|
| Stomach |
|
| |||||
Male | 1 | 2.3 | nc | (nc-nc) |
| Male | 0 | 1.2 | nc | (nc-nc) |
Female | 3 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |
Larynx |
|
| Testis |
|
| |||||
Male | 1 | 0.8 | nc | (nc-nc) |
| Male | 0 | 0.6 | nc | (nc-nc) |
Female | 1 | 0.2 | nc | (nc-nc) |
|
|
|
|
|
|
Leukemia |
|
| Thyroid |
|
| |||||
Male | 1 | 1.7 | nc | (nc-nc) |
| Male | 1 | 0.7 | nc | (nc-nc) |
Female | 0 | 1.3 | nc | (nc-nc) |
| Female | 2 | 2.3 | nc | (nc-nc) |
Liver and Intrahepatic Bile Ducts |
|
| Uteri Corpus and Uterus, NOS |
|
| |||||
Male | 1 | 1.1 | nc | (nc-nc) |
|
|
|
|
|
|
Female | 1 | 0.4 | nc | (nc-nc) |
| Female | 5 | 3.7 | 134.8 | (43.4-314.5) |
Lung and Bronchus |
|
| All Sites / Types |
|
| |||||
Male | 13 | 9.4 | 137.9 | (73.3-235.8) |
| Male | 65 | 65.7 | 98.9 | (76.4-126.1) |
Female | 8 | 8.6 | 93.0 | (40.0-183.2) |
| Female | 70 | 59.9 | 116.9 | (91.1-147.7) |
• Obs = observed case count; Exp = expected case count;
• SIR = standardized incidence ratio ( (Obs / Exp) X 100);
• 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
• Shading indicates the statistical significance of the SIR at 95% level of probability;
• nc = The SIR and 95% CI were not calculated when Obs < 5;
329
West Boylston
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006
| Obs | Exp | SIR | 95% CI |
|
| Obs | Exp | SIR | 95% CI |
Bladder, Urinary |
|
| Melanoma of Skin |
|
| |||||
Male | 6 | 9.0 | 66.5 | (24.3-144.7) |
| Male | 3 | 5.8 | nc | (nc-nc) |
Female | 1 | 3.0 | nc | (nc-nc) |
| Female | 5 | 3.8 | 130.0 | (41.9-303.5) |
Brain and Other Nervous System |
|
| Multiple Myeloma |
|
| |||||
Male | 2 | 1.8 | nc | (nc-nc) |
| Male | 1 | 1.4 | nc | (nc-nc) |
Female | 2 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |
Breast |
|
| Non-Hodgkin Lymphoma |
|
| |||||
Male | 1 | 0.3 | nc | (nc-nc) |
| Male | 6 | 5.0 | 120.8 | (44.1-262.9) |
Female | 31 | 28.1 | 110.3 | (74.9-156.6) |
| Female | 5 | 3.8 | 130.1 | (41.9-303.7) |
Cervix Uteri |
|
| Oral Cavity & Pharynx |
|
| |||||
|
|
|
|
|
| Male | 1 | 3.5 | nc | (nc-nc) |
Female | 3 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |
Colon / Rectum |
|
| Ovary |
|
| |||||
Male | 8 | 12.7 | 63.0 | (27.1-124.1) |
|
|
|
|
|
|
Female | 4 | 11.0 | nc | (nc-nc) |
| Female | 5 | 2.9 | 169.7 | (54.7-396.0) |
Esophagus |
|
| Pancreas |
|
| |||||
Male | 3 | 2.3 | nc | (nc-nc) |
| Male | 4 | 2.7 | nc | (nc-nc) |
Female | 0 | 0.6 | nc | (nc-nc) |
| Female | 2 | 2.6 | nc | (nc-nc) |
Hodgkin Lymphoma |
|
| Prostate |
|
| |||||
Male | 1 | 0.9 | nc | (nc-nc) |
| Male | 24 | 32.6 | 73.7 | (47.2-109.7) |
Female | 1 | 0.4 | nc | (nc-nc) |
|
|
|
|
|
|
Kidney & Renal Pelvis |
|
| Stomach |
|
| |||||
Male | 5 | 4.3 | 117.1 | (37.7-273.3) |
| Male | 0 | 2.1 | nc | (nc-nc) |
Female | 2 | 2.3 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |
Larynx |
|
| Testis |
|
| |||||
Male | 1 | 1.4 | nc | (nc-nc) |
| Male | 0 | 1.7 | nc | (nc-nc) |
Female | 0 | 0.3 | nc | (nc-nc) |
|
|
|
|
|
|
Leukemia |
|
| Thyroid |
|
| |||||
Male | 1 | 3.0 | nc | (nc-nc) |
| Male | 2 | 1.6 | nc | (nc-nc) |
Female | 5 | 2.1 | 243.1 | (78.3-567.3) |
| Female | 2 | 3.5 | nc | (nc-nc) |
Liver and Intrahepatic Bile Ducts |
|
| Uteri Corpus and Uterus, NOS |
|
| |||||
Male | 1 | 2.1 | nc | (nc-nc) |
|
|
|
|
|
|
Female | 0 | 0.6 | nc | (nc-nc) |
| Female | 8 | 6.2 | 129.1 | (55.6-254.4) |
Lung and Bronchus |
|
| All Sites / Types |
|
| |||||
Male | 14 | 16.5 | 84.6 | (46.2-142.0) |
| Male | 92 | 119.8 | 76.8 | (61.9-94.2) |
Female | 13 | 14.3 | 90.9 | (48.4-155.4) |
| Female | 96 | 99.8 | 96.2 | (77.9-117.4) |
• Obs = observed case count; Exp = expected case count;
• SIR = standardized incidence ratio ( (Obs / Exp) X 100);
• 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
• Shading indicates the statistical significance of the SIR at 95% level of probability;
• nc = The SIR and 95% CI were not calculated when Obs < 5;
330
West Bridgewater
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006
| Obs | Exp | SIR | 95% CI |
|
| Obs | Exp | SIR | 95% CI |
Bladder, Urinary |
|
| Melanoma of Skin |
|
| |||||
Male | 8 | 9.3 | 86.1 | (37.1-169.7) |
| Male | 6 | 5.4 | 110.5 | (40.4-240.5) |
Female | 7 | 3.6 | 194.8 | (78.0-401.3) |
| Female | 4 | 4.4 | nc | (nc-nc) |
Brain and Other Nervous System |
|
| Multiple Myeloma |
|
| |||||
Male | 0 | 1.6 | nc | (nc-nc) |
| Male | 1 | 1.4 | nc | (nc-nc) |
Female | 2 | 1.4 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |
Breast |
|
| Non-Hodgkin Lymphoma |
|
| |||||
Male | 0 | 0.3 | nc | (nc-nc) |
| Male | 5 | 4.7 | 106.5 | (34.3-248.4) |
Female | 27 | 32.0 | 84.3 | (55.5-122.6) |
| Female | 5 | 4.5 | 110.1 | (35.5-257.0) |
Cervix Uteri |
|
| Oral Cavity & Pharynx |
|
| |||||
|
|
|
|
|
| Male | 4 | 3.3 | nc | (nc-nc) |
Female | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |
Colon / Rectum |
|
| Ovary |
|
| |||||
Male | 10 | 12.8 | 78.3 | (37.5-143.9) |
|
|
|
|
|
|
Female | 12 | 13.2 | 91.1 | (47.0-159.2) |
| Female | 1 | 3.4 | nc | (nc-nc) |
Esophagus |
|
| Pancreas |
|
| |||||
Male | 4 | 2.3 | nc | (nc-nc) |
| Male | 5 | 2.8 | 180.2 | (58.1-420.5) |
Female | 0 | 0.7 | nc | (nc-nc) |
| Female | 2 | 3.1 | nc | (nc-nc) |
Hodgkin Lymphoma |
|
| Prostate |
|
| |||||
Male | 2 | 0.7 | nc | (nc-nc) |
| Male | 36 | 33.8 | 106.6 | (74.6-147.6) |
Female | 1 | 0.5 | nc | (nc-nc) |
|
|
|
|
|
|
Kidney & Renal Pelvis |
|
| Stomach |
|
| |||||
Male | 4 | 4.1 | nc | (nc-nc) |
| Male | 3 | 2.1 | nc | (nc-nc) |
Female | 2 | 2.7 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |
Larynx |
|
| Testis |
|
| |||||
Male | 2 | 1.4 | nc | (nc-nc) |
| Male | 0 | 1.0 | nc | (nc-nc) |
Female | 0 | 0.4 | nc | (nc-nc) |
|
|
|
|
|
|
Leukemia |
|
| Thyroid |
|
| |||||
Male | 0 | 2.9 | nc | (nc-nc) |
| Male | 2 | 1.3 | nc | (nc-nc) |
Female | 1 | 2.4 | nc | (nc-nc) |
| Female | 4 | 3.8 | nc | (nc-nc) |
Liver and Intrahepatic Bile Ducts |
|
| Uteri Corpus and Uterus, NOS |
|
| |||||
Male | 2 | 2.0 | nc | (nc-nc) |
|
|
|
|
|
|
Female | 0 | 0.8 | nc | (nc-nc) |
| Female | 7 | 7.2 | 97.2 | (38.9-200.2) |
Lung and Bronchus |
|
| All Sites / Types |
|
| |||||
Male | 19 | 17.0 | 111.7 | (67.2-174.5) |
| Male | 120 | 119.3 | 100.6 | (83.4-120.3) |
Female | 19 | 17.0 | 112.0 | (67.4-174.9) |
| Female | 102 | 116.2 | 87.8 | (71.6-106.6) |
• Obs = observed case count; Exp = expected case count;
• SIR = standardized incidence ratio ( (Obs / Exp) X 100);
• 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
• Shading indicates the statistical significance of the SIR at 95% level of probability;
• nc = The SIR and 95% CI were not calculated when Obs < 5;
331
West Brookfield
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006
| Obs | Exp | SIR | 95% CI |
|
| Obs | Exp | SIR | 95% CI |
Bladder, Urinary |
|
| Melanoma of Skin |
|
| |||||
Male | 3 | 5.2 | nc | (nc-nc) |
| Male | 1 | 3.0 | nc | (nc-nc) |
Female | 0 | 2.6 | nc | (nc-nc) |
| Female | 0 | 2.8 | nc | (nc-nc) |
Brain and Other Nervous System |
|
| Multiple Myeloma |
|
| |||||
Male | 1 | 0.8 | nc | (nc-nc) |
| Male | 0 | 0.8 | nc | (nc-nc) |
Female | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |
Breast |
|
| Non-Hodgkin Lymphoma |
|
| |||||
Male | 2 | 0.2 | nc | (nc-nc) |
| Male | 5 | 2.6 | 191.0 | (61.6-445.8) |
Female | 11 | 20.6 | 53.5 | (26.7-95.7) |
| Female | 0 | 3.2 | nc | (nc-nc) |
Cervix Uteri |
|
| Oral Cavity & Pharynx |
|
| |||||
|
|
|
|
|
| Male | 0 | 1.8 | nc | (nc-nc) |
Female | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |
Colon / Rectum |
|
| Ovary |
|
| |||||
Male | 6 | 7.1 | 84.1 | (30.7-183.1) |
|
|
|
|
|
|
Female | 11 | 10.1 | 108.9 | (54.3-194.8) |
| Female | 3 | 2.3 | nc | (nc-nc) |
Esophagus |
|
| Pancreas |
|
| |||||
Male | 1 | 1.3 | nc | (nc-nc) |
| Male | 3 | 1.5 | nc | (nc-nc) |
Female | 0 | 0.5 | nc | (nc-nc) |
| Female | 5 | 2.3 | 215.1 | (69.3-501.9) |
Hodgkin Lymphoma |
|
| Prostate |
|
| |||||
Male | 0 | 0.3 | nc | (nc-nc) |
| Male | 20 | 17.8 | 112.4 | (68.6-173.6) |
Female | 0 | 0.3 | nc | (nc-nc) |
|
|
|
|
|
|
Kidney & Renal Pelvis |
|
| Stomach |
|
| |||||
Male | 2 | 2.2 | nc | (nc-nc) |
| Male | 0 | 1.2 | nc | (nc-nc) |
Female | 3 | 1.7 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |
Larynx |
|
| Testis |
|
| |||||
Male | 0 | 0.8 | nc | (nc-nc) |
| Male | 0 | 0.5 | nc | (nc-nc) |
Female | 0 | 0.2 | nc | (nc-nc) |
|
|
|
|
|
|
Leukemia |
|
| Thyroid |
|
| |||||
Male | 1 | 1.6 | nc | (nc-nc) |
| Male | 0 | 0.7 | nc | (nc-nc) |
Female | 2 | 1.8 | nc | (nc-nc) |
| Female | 3 | 2.2 | nc | (nc-nc) |
Liver and Intrahepatic Bile Ducts |
|
| Uteri Corpus and Uterus, NOS |
|
| |||||
Male | 0 | 1.1 | nc | (nc-nc) |
|
|
|
|
|
|
Female | 0 | 0.6 | nc | (nc-nc) |
| Female | 4 | 4.4 | nc | (nc-nc) |
Lung and Bronchus |
|
| All Sites / Types |
|
| |||||
Male | 9 | 9.0 | 100.0 | (45.6-189.9) |
| Male | 58 | 64.8 | 89.6 | (68.0-115.8) |
Female | 3 | 11.0 | nc | (nc-nc) |
| Female | 48 | 78.6 | 61.1 | (45.0-81.0) |
• Obs = observed case count; Exp = expected case count;
• SIR = standardized incidence ratio ( (Obs / Exp) X 100);
• 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
• Shading indicates the statistical significance of the SIR at 95% level of probability;
• nc = The SIR and 95% CI were not calculated when Obs < 5;
332
West Newbury
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006
| Obs | Exp | SIR | 95% CI |
|
| Obs | Exp | SIR | 95% CI |
Bladder, Urinary |
|
| Melanoma of Skin |
|
| |||||
Male | 4 | 3.9 | nc | (nc-nc) |
| Male | 1 | 2.8 | nc | (nc-nc) |
Female | 3 | 1.3 | nc | (nc-nc) |
| Female | 8 | 2.2 | ||